WO2026026878 - HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION THEREOF AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/026878
Publication Date
05.02.2026
International Application No.
PCT/CN2025/111601
International Filing Date
30.07.2025
Title **
[English]
HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION THEREOF AND USE THEREOF
[French]
INHIBITEUR DÉRIVÉ HÉTÉROCYCLIQUE, SA PRÉPARATION ET SON UTILISATION
[Chinese]
一种杂环衍生物抑制剂及其制备和用途
Applicants **
CHENGDU SHIBEIKANG BIOMEDICAL TECHNOLOGY CO., LTD.
Inventors
ZENG, Yanqun
HUANG, Long
Priority Data
202411026610.9
30.07.2024
CN
202411909671.X
24.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1798 | |
| EPO | Filing, Examination, Granting | 12186 | |
| Japan | Filing, Examination, Granting | 1998 | |
| South Korea | Filing, Examination, Granting | 1837 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,559
Contact Us
Abstract[English]
The present invention belongs to the field of drug synthesis, and specifically relates to a heterocyclic derivative inhibitor, and the preparation thereof and the use thereof. Disclosed in the present invention is a compound having a structure as represented by formula I, or an isomer or pharmaceutically acceptable salt thereof. The compound of formula I provided by the present invention has strong PCSK9 inhibitory activity, and can be used for treating and/or preventing cardiovascular and cerebrovascular diseases.[French]
La présente invention relève du domaine de la synthèse de médicaments, et concerne spécifiquement un inhibiteur dérivé hétérocyclique, sa préparation et son utilisation. La présente invention concerne un composé ayant une structure telle que représentée par la formule I, ou un isomère ou un sel pharmaceutiquement acceptable de celui-ci. Le composé de formule I selon la présente invention présente une forte activité inhibitrice de PCSK9, et peut être utilisé pour traiter et/ou prévenir des maladies cardiovasculaires et cérébrovasculaires.[Chinese]
本发明属于药物合成领域，具体涉及一种杂环衍生物抑制剂及其制备和用途。本发明公开了一种结构如式Ⅰ的化合物或其异构体、药学上可接受的盐，本发明提供的式Ⅰ化合物具有较强的PCSK9抑制活性，可用于治疗和/或预防心血管及脑血管疾病。